GlassScriptPhysician profile
Swathi Singanamala
NPI 1023275617
$5,058.39
in general payments reported to CMS, 2019-2025
27 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $467 · 2021: $850 · 2022: $915 · 2023: $980 · 2024: $810 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,139 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,138.68 |
| Education | $169.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $579.39 | 2019-2025 | Veltassa, Korsuva |
| Horizon Therapeutics Plc | $555.93 | 2019-2023 | Krystexxa |
| Amgen INC. | $471.59 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $431.24 | 2021-2025 | |
| Daiichi Sankyo INC. | $416.68 | 2019-2025 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $398.97 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $319.05 | 2019-2023 | Farxiga, Lokelma |
| Aurinia Pharma U.S., INC. | $296.76 | 2021-2025 | Lupkynis |
| Akebia Therapeutics INC | $255.23 | 2019-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $251.75 | 2020-2025 | Filspari |
| Baxter Healthcare | $160.27 | 2019-2023 | Renal - Pd |
| Fresenius USA Marketing, INC. | $149.24 | 2019-2024 | Velphoro |
| Novartis Pharmaceuticals Corporation | $141.80 | 2024-2025 | |
| Ardelyx, INC. | $94.87 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $87.17 | 2022-2023 | Benlysta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $80.93 | 2020-2022 | |
| Calliditas Therapeutics US INC. | $70.58 | 2022-2025 | Tarpeyo |
| Xeris Pharmaceuticals, INC. | $60.32 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $42.52 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $41.10 | 2019 | |
| Apellis Pharmaceuticals, INC. | $30.65 | 2025 | Empaveli |
| Scpharmaceuticals INC. | $24.64 | 2023 | |
| Novo Nordisk INC | $22.56 | 2025 | Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $22.26 | 2020 | |
| Lilly USA, LLC | $21.76 | 2024 | Jardiance |
| Boston Scientific Corporation | $18.36 | 2025 | Opticross 35 |
| Ultragenyx Pharmaceutical INC. | $12.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swathi Singanamala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.